title: A phase 2 study of vatalanib in metastatic melanoma patients.
abstract: BACKGROUND
  A phase 2 study of vatalanib (PTK787/ZK222584) an oral tyrosine kinase inhibitor of VEGFR 1, 2 and 3 was undertaken in patients with metastatic melanoma.
  
  
  METHODS
  Adults with pathologically confirmed metastatic melanoma, WHO Performance status 0-2, and adequate haematological, hepatic and renal function, were treated with vatalanib until disease progression. The trial used Fleming's single stage design.
  
  
  RESULTS
  Tumour control rate (CR+PR+SD) was 35% at 16 weeks, with objective response seen in only 1 patient. Median progression-free survival was 1.8 months (95% CI 1.8-3.7 months) and median overall survival was 6.5 months (95% CI 3.9-10.2 months).
  
  
  CONCLUSIONS
  Vatalanib stabilised disease in a proportion of patients, although overall survival was disappointing.
authors.affiliation: Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK.
authors.forename: Natalie
authors.initials: N
authors.lastname: Cook
authors.forename: Bristi
authors.initials: B
authors.lastname: Basu
authors.forename: Swethajit
authors.initials: S
authors.lastname: Biswas
authors.forename: Paula
authors.initials: P
authors.lastname: Kareclas
authors.forename: Colette
authors.initials: C
authors.lastname: Mann
authors.forename: Cheryl
authors.initials: C
authors.lastname: Palmer
authors.forename: Anne
authors.initials: A
authors.lastname: Thomas
authors.forename: Steve
authors.initials: S
authors.lastname: Nicholson
authors.forename: Bruno
authors.initials: B
authors.lastname: Morgan
authors.forename: David
authors.initials: D
authors.lastname: Lomas
authors.forename: Bhawna
authors.initials: B
authors.lastname: Sirohi
authors.forename: Adrian P
authors.initials: AP
authors.lastname: Mander
authors.forename: Mark
authors.initials: M
authors.lastname: Middleton
authors.forename: Pippa G
authors.initials: PG
authors.lastname: Corrie
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D010793:Phthalazines / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D010793:Phthalazines; D011725:Pyridines; C404768:vatalanib